Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals is a clinical-stage biotechnology startup that focuses on developing metabolic oncology therapeutics for hard-to-treat cancers. The company's slogan "Rare Science. Rare Compassion. Rare Solutions." emphasizes its dedication to addressing the unique needs of patients with rare cancers. Its deep understanding of cancer-specific bio-energetic processes has led to the discovery of novel drugs and drug delivery technologies with the potential to revolutionize cancer treatment.

Founded in 2001 and headquartered in the United States, Cornerstone Pharmaceuticals aims to produce highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues. The company's lead drug, CPI-613, targets enzymes involved in cancer cell energy metabolism and is being evaluated in multiple Phase I, I/II, and II clinical studies as a single agent and in combination with standard drug therapy.

With a focus on attacking regulatory processes exclusive to cancer cells, Cornerstone Pharmaceuticals aims to improve the safety profile and efficacy of cancer treatment. As the company continues to advance its groundbreaking research in altered cancer metabolism directed therapies, it presents an opportunity for venture capitalists to support innovative approaches to tackling challenging aspects of cancer treatment. While the specific details of the last investment and investors are not available, the potential for investing in Cornerstone Pharmaceuticals aligns with the growing interest in biotechnology and pharmaceutical companies at the forefront of developing targeted therapies for cancer.